The Enrollment Table Is the First Safety Review: Who Is Missing From Modern Pain Trials
In November 2026, a pain-drug press release can travel farther than the paper behind it. A single sentence about average pain relief may reach patients, clinicians, investors, and payers before anyone opens the enrollment table. For experimental pain therapies, including the NGF inhibitors that followed tanezumab through years of joint-safety scrutiny, that table is often more useful than the headline. It tells you who was studied, who was excluded, and therefore who the result might actually describe.
The Average Patient Is a Statistical Convenience
A randomized trial can be well powered, well conducted, and still narrow. The primary result is an average treatment effect: the difference between groups across the people who enrolled. That average may be true and still not transportable to the patient in front of you. Generalizability is not a mood or a marketing claim. It is an empirical question about whether the trial population resembles the population that will use the drug.
Pain research has a particular version of this problem. The U.S. pain burden is concentrated in older adults, people with multiple chronic conditions, rural residents, and Black and Hispanic patients, among other groups. Those are also groups that clinical trial systems often struggle to enroll. A trial in knee osteoarthritis may report a modest average improvement while enrolling few patients over 75, few patients with advanced kidney disease, and few patients whose daily lives include several pain conditions at once.
Four Gaps That Rewrite a Result
The first gap is age. Many pain trials set upper age limits or use frailty, renal function, and polypharmacy rules that quietly filter out older adults. Yet older adults are among the heaviest users of analgesics and the most likely to experience drug-related harm. A tanezumab-style joint-safety question is especially sensitive here. If a trial excluded people with severe baseline joint damage or prior joint replacement, its safety estimate may not describe a Medicare patient with long-standing knee osteoarthritis.
The second gap is race and ethnicity. Black and Hispanic patients often carry a disproportionate share of chronic pain and disability, but trial sites cluster around academic centers that may be far from their communities. Language barriers, transportation costs, distrust shaped by past research abuses, and narrow eligibility criteria all compound the problem. An enrollment table showing 80 percent white participants in a disease with a diverse burden is not a neutral fact. It is a limit on what the trial can claim.
The third gap is geography. Rural residents may live hours from the nearest research site and may be unable to attend frequent visits. A trial that enrolls mostly urban and suburban patients can still produce a valid result, but it cannot automatically speak for rural pain care. Site lists on ClinicalTrials.gov are worth reading alongside the paper.
The fourth gap is multimorbidity. People with several chronic conditions are often excluded through lab thresholds, medication rules, or concerns about confounding. That keeps trials cleaner and less representative. A patient with diabetes, hypertension, and osteoarthritis may be precisely the person a new pain drug will reach in practice, yet be absent from the evidence base.
How to Read an Enrollment Table in Ten Minutes
Start with the baseline table, not the abstract. Look at mean age and its spread. A mean age of 61 with a standard deviation of 9 suggests few participants over 75. Check the proportion over 65 and over 75 separately. Then check race and ethnicity against the burden of the condition in the U.S., not against the convenience of the site network.
Next, read the eligibility criteria for exclusions that matter in practice: renal impairment, cardiovascular disease, prior joint replacement, opioid use, obesity, and psychiatric conditions. Then look at baseline pain and function scores. A trial that enrolls patients with moderate pain may not predict effects in patients with severe pain. A trial that enrolls patients with early joint disease may not predict joint safety in advanced disease.
Finally, look for prespecified subgroup analyses. A claim that a drug works across groups should be supported by interaction tests and confidence intervals, not by a sentence in the discussion. If older adults were only 8 percent of the sample, a subgroup estimate will be imprecise. That does not make it wrong. It makes it uncertain.
What Generalizability Should Require
A credible generalizability claim needs more than the word diverse. It needs disaggregated enrollment, a comparison to the target population, prespecified subgroup analyses, and absolute risk differences. For safety, it needs enough older adults and enough patients with joint disease to detect the events that matter. For a tanezumab-style program, the central question was never only whether pain improved on average. It was whether joint-related harm would outweigh that benefit in the patients most likely to receive the drug.
Questions for the Appointment
When a pain-drug result appears in the news, bring three questions to your clinician or your reading group. Would the patients in this trial look like me or the people I treat? Were the groups most likely to be harmed included in enough numbers to detect harm? And does the paper report subgroup results, or only an average?
The enrollment table is not glamorous. It is the first safety review and the first relevance review. Before a pain-drug result is applied to a patient, someone should be able to say who was counted, who was missing, and what that means for the person in the exam room.